Skip to main content
Delfa

← All trials/NCT03182192

UnknownPhase 1

GLP1R-imaging in Hypoglycemia

Visualizing Beta Cells in Patients With Hyperinsulinemic Hypoglycemia After Bariatric Surgery

Asset

Exenatide

GLP-1 agonist

Listed sites

2

Recruiting sites

2

Estimated enrollment

12

Study population

Bariatric Surgery

Eligibility highlights

-

Primary endpoint

•Uptake of 68Ga-exendin in the pancreas of patients

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03182192
Org study IDNL51854.091.15

Timeline

Milestones

Study start2016-04-01actual
Study first posted2017-06-09actual
Last update posted2023-12-08actual
Primary completion2024-07-01estimated
Study completion2024-07-01estimated

Assets

Investigational agents

Exenatide

Who this study enrolls

Bariatric Surgery

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

All individuals:

•Signed informed consent
•> 18

Additional for matched control group:

•RYGB at least 2 years ago
•Normal glucose levels before and after RYGB
•Score <7 on Sigstad's scoring system
•Individual matched to HH group on age

Exclusion criteria

All individuals:

•Anti-diabetic medication in the past 6 months
•Treatment with synthetic exendin in the past 6 months
•Liver failure
•Pregnancy
•Breast feeding
•Kidney failure
•Age < 18
•No signed informed consent

Additional for matched control group:

•Any diabetic history
•Previous diagnosed HH
•Sigstad's dumping score >7

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
1
Other (unclassified)
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint/low confidence

Correlation of tracer uptake with C-peptide and HbA1c

Time frame:1 year

descriptive

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Uptake of 68Ga-exendin in the pancreas of patients

Time frame:1 year

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.